Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

Key Points

• Inventiva S.A. Sponsored ADR experienced a significant increase in short interest, rising by 53.1% in August to a total of 44,100 shares.
• IVA stock is currently valued at $5.31 after a 5.3% decline, with a consensus target price of $14.83 based on analyst ratings.
• Institutional investors hold 19.06% of Inventiva's stock, with Wealth Enhancement Advisory Services recently acquiring 10,715 shares valued at approximately $32,000.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 44,100 shares, a growth of 53.1% from the August 15th total of 28,800 shares. Based on an average daily volume of 35,900 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.1% of the shares of the stock are sold short. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 35,900 shares, the days-to-cover ratio is presently 1.2 days.

Inventiva Stock Down 5.3%

IVA stock traded down $0.30 during trading hours on Monday, hitting $5.31. 27,138 shares of the stock were exchanged, compared to its average volume of 24,229. The company has a 50-day simple moving average of $4.15 and a two-hundred day simple moving average of $3.56. Inventiva has a 12 month low of $1.53 and a 12 month high of $6.50.

Analyst Upgrades and Downgrades

IVA has been the topic of several recent analyst reports. HC Wainwright assumed coverage on shares of Inventiva in a research note on Wednesday, September 3rd. They issued a "buy" rating and a $20.00 target price on the stock. Piper Sandler initiated coverage on Inventiva in a research note on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price on the stock. Finally, Guggenheim raised their target price on Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $14.83.

Institutional Investors Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.